ClinicalTrials.gg
RecruitingNCT06502717Updated Jan 29, 2025

Viome Precision Nutritional Programs to Improve Clinical Outcomes for Mental Health Disorders

An interventional study of VIOME Precision Nutrition Program in Mental Health Issue, Depression and Anxiety, sponsored by Viome. Recruiting at 1 site in United States. Open to participants aged 25 Years to 75 Years. Per ClinicalTrials.gov, last updated 2025-01-29.

Sponsored by Viome · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by Dec 2025, 11 months ago, but the record still lists the study as recruiting.
  • Started Jul 2024; still recruiting 2 years 4 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
150
Allocation
Randomized
Ages
25 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 3,715 studies in Depression with a site in United States — 579 open to participants now, 716 under way, 29 of them phase 3. Depression · United States.

Planned enrollment
1,020th of 3,322
150 · median 72
Started
2024
with 212 others
No phase
2,221 of 3,715
386 open now
Primary completion
2025-12
later than 67 of 714 live
Registered
3,266th of 3,715
by date

Among the 3,715 studies in Depression with a site in United States, this one is the 1,020th largest by planned enrollment of the 3,322 interventional ones that give a count, is one of 213 that started in 2024, is one of 2,221 with no phase, reaches primary completion later than 67 of the 714 other live ones, and was the 3,266th registered.

Depression

8,608 studies on the registry are indexed under Depression; 1,736 are open to participants now.

Browse Depression studies →

Open to participants now

579 of the 3,715 studies in Depression with a site in United States are open now. Recruiting first, the newest first:

574 more — sign in →

All 579 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 1,098 Depression studies recruiting now, 475 (43%) set no upper age limit and 522 (48%) stop at 75 or younger; 205 take children under 18; 315 take healthy volunteers.

This study: 25 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 3,715 studies in Depression with a site in United States, or all of them as a file.
02

Study summary

US residents who have mental health issues sign the informed consent form and are screened and enrolled for this study. Participants complete a survey upon enrollment and are randomized into one of two study arms. This study is direct to participant and will NOT utilize clinical sites.

Read the detailed description

Participants who meet the eligibility criteria are randomized into any of the two study arms including: the placebo arm or the VIOME Precision Nutrition Program (VPNP) arm.

Placebo and Viome's Precision Nutrition Program include supplements, may include dietary recommendations towards improving the symptoms associated with mental health. The trial will last approximately 4 months for each participant.

03

Conditions studied

  • Mental Health Issue
  • Depression
  • Anxiety

Keywords

  • mental health
  • diet
  • supplements
  • vitamins
  • stress
04

Who can participate

Ages eligible
25 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Resident of the United States
  • Females and males ages 25-75 (inclusive)
  • Able to speak and read English
  • No unexplained weight loss, fevers, anemia, or blood in stool
  • Willing and able to follow the trial instructions, as described in the recruitment letter
  • Signed and dated prior to any trial-specific procedures.
  • PHQ9 score of 5-24 (inclusive)

Exclusion criteria

Exclusion Criteria:

  • Unwilling to change their current diet
  • Prior use of Viome products or services
  • Antibiotic use in the previous 4 weeks
  • Pregnancy (current or planned in the next 4 months)
  • \< 90 days postpartum
  • Breast feeding
  • Active infection
  • Unable or unwilling to use Viome's App on an iPhone or Android smartphone
  • Significant diet or lifestyle change in the previous 1 month
  • IBD diagnosis -Major psychiatric/DSM-4 disease diagnosis (e.g. Schizophrenia, Bipolar disorder, Post- traumatic Stress Disorder, Obsessive Compulsive disorder)
  • Use of drugs, products or devices within 1 month prior to and 4 months after the start of the trial
  • Cancer therapy within the previous 1 year
  • Major surgery in the last 6 months or planned in the next 4 months
  • Allergies to any supplement ingredients listed in the screening survey
  • Currently on a specific diet: FODMAP, KETO, PALEO
  • Answered yes to the question, "In the past few weeks, have you wished you were dead or had thoughts about killing yourself?"
  • Gastrointestinal disease including:

    • GI surgery except:

      • Appendectomy and benign polypectomy
  • Esophagitis
  • Celiac disease
  • GI or obstruction
  • Peptic Ulcer Disease
  • Duodenal or gastric ulcer disease
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Participant)
Enrollment
150 participants (estimated)

Study arms

  • No intervention
    Placebo

    Participants who have mental health issues are randomized into this study arm. They may be provided with any combination of nutritional recommendations and supplements. Placebo capsules will contain inert or inactive ingredients. Participants may need to use a mobile app in order to participate in the trial.

  • Active comparator
    Viome's Precision Nutrition Program (VPNP)

    Participants who have mental health issues are randomized into this arm. They may be provided with any combination of nutritional recommendations and supplements. Participants may need to use a mobile app in order to participate in the trial.

    Combination Product: VIOME Precision Nutrition Program

Interventions

  • Combination productVIOME Precision Nutrition Program

    Precision supplement based on the participants microbiome sample results. Participants in this arm may have any combination of supplements, diet recommendations, and/or coaching.

    Also known as: VPNP

06

What researchers measure

Primary outcomes

  1. Reduced PHQ-9 Score

    Reduced PHQ-9 score for the VPNP group compared to baseline scores.

    Time frame: ~4 months

  2. Reduced GAD-7 Score

    Reduced GAD-7 score for the VPNP groups compared to baseline scores.

    Time frame: ~4 months

  3. Reduced Perceived Stress Scale Score

    Reduced Perceived Stress Scale score for the VPNP group compared to baseline scores.

    Time frame: ~4 months

  4. Increased Quality of Life Score

    Increased quality of life score for the VPNP group compared to baseline scores.

    Time frame: ~4 months

  5. Correlation between microbial changes and clinical outcomes

    Correlation between microbial changes on the VPNP with clinical outcomes.

    Time frame: ~4 months

07

Study locations

1 of 1 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jul 2024 (actual). Primary completion is estimated for Dec 2025, 17 months after the start.

Of 98 industry-sponsored interventional studies with no phase under Depression, half reached primary completion within 9 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 18. This study's planned 17 months is above that.

Counting every sponsor, half of 3,584 studies reached it within 21 months; a quarter within 9 and three quarters within 41.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 25, 2024
First posted
Jul 16, 2024
StartActual
Jul 8, 2024
Primary completionEst.
Dec 2025
CompletionEst.
Dec 2025
Last update
Jan 29, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 29, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06502717
Lead sponsor
Viome
Responsible party
Sponsor
First posted
Jul 16, 2024
Start date
Jul 8, 2024
Primary completion
Dec 2025 (estimated)
Completion
Dec 2025 (estimated)
Last update
Jan 29, 2025

Study contacts

Mory Mehrtash
Contact
studies@viome.com
(425) 300-6933
Momchilo Vuyisich
Contact
studies@viome.com
(425) 300-6933
Momchilo Vuyisich
principal investigator · Viome

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion